Low-molecular weight heparins.
Talley
J D
JD
Department of Internal Medicine, UAMS, USA.
D000789:Angina, Unstable / Q000188:drug therapy; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D000991:Antithrombins / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017985:Dalteparin / Q000008:administration & dosage / Q000627:therapeutic use; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D009203:Myocardial Infarction / Q000188:drug therapy; D017762:Nadroparin / Q000008:administration & dosage / Q000627:therapeutic use; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use; D013923:Thromboembolism / Q000517:prevention & control
D000925:Anticoagulants; D000991:Antithrombins; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D010880:Piperidines; C099871:inogatran; D017985:Dalteparin; D005998:Glycine